Advanced Packaging Reshapes Chip Industry in 2025
Revance's Botox Rival Receives USFDA Nod
By Indu Tyagi Ketan , 19 October, 2022
DaxibotulinumtoxinA (Daxxify), Revance's long-awaited Botox rival, has officially received FDA approval, as the company is now gearing up to establish its brand. Daxxify is an intravenous neuromodulator similar to Botox; its novel peptide exchange technology temporarily eases the moderate to severe glabellar (frown) lines.
The trials revealed that a single injection had a significant anti-wrinkle impact on durational effects were proven in phase 3 trials with 4,200 treatments and 2,700 patients. The chief differentiator for Daxxify is its endurance; it can last six months and has even proven effective for up to nine months in some individuals, vis-a-vis Botox injections that last only for three months.
Daxxify was initially scheduled to receive FDA approval in November 2020, but the epidemic slowed inspection. After visiting Revance's production facility, inspectors discovered quality control and record-keeping issues. The FDA then issued Revance a detailed response letter in October of last year. Soon after, the FDA approved the changes in July after Revance resolved all five problems mentioned in the Complete Response Letter.
In a separate report, Goldman Sachs predicted that Revance's Daxxify will cost about 30% more than its competitors, even though pricing has not yet been made public. This cost considers the extended value proposition for both doctors and patients. Revance's stock rose 18% in September post the FDA's approval, which is expected to end Botox's long-standing dominance in the aesthetics industry.
FDA Approves DaxibotulinumtoxinA (Daxxify)
Latest News
Advanced Packaging Reshapes Chip Industry in 2025
The world of semiconductors is evolving with new advanced multichip packaging innovations in 2025. Due to the advancements, the chip's performance improves, mobile devices and new GenAI technology can be produced promptly, and production and…
AI Reinvents Energy Efficiency in Building Designs 2025: A Novel Approach to Clean Energy Transition
In 2025, AI technology will change energy efficiency in buildings, marking another milestone in the shift towards renewable energy. With AI, Building Management Systems (BMS) can now guarantee energy monitoring and optimization, which minimizes waste…
Big Tech Backs Nuclear Expansion: Pledges to Triple Global Capacity by 2050
Leading technology giants Amazon, Google, and Meta have teamed up with other big energy users in a historic action at the CERAWeek 2025 energy conference in Houston to promote an ambitious initiative: doubling world nuclear power capacity by 2025…
China’s Refining Industry Sees 2.1% Growth in Early 2025 Amid Rising Fuel Demand and Geopolitical Shifts
China's refining sector showed resilience and adaptability in the first months of 2025, raising crude oil throughput by 2.1 percent over the year before. According to the National Bureau of Statistics, this increase resulted in a processing volume of…
Elsevier Unveils ScienceDirect AI in 2025 to Revolutionize Research Efficiency
In March 2025, Elsevier launched ScienceDirect AI, a world-renowned leader in science and health information science. This state-of-the-art generative AI tool can potentially transform the industry with its revolutionary advances in research. This…
Indu Tyagi Ketan
Chief Strategy Officer
Latest News
AI Reinvents Energy Efficiency in Building Designs 2025: A Novel Approach to Clean Energy Transition
Big Tech Backs Nuclear Expansion: Pledges to Triple Global Capacity by 2050
China’s Refining Industry Sees 2.1% Growth in Early 2025 Amid Rising Fuel Demand and Geopolitical Shifts
Elsevier Unveils ScienceDirect AI in 2025 to Revolutionize Research Efficiency
